Compass Therapeutics Inc. expected to post a loss of 12 cents a share - Earnings Preview

Compass Therapeutics

08/08/2025 18:51

Compass Therapeutics Inc. CMPX.OQ CMPX.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Compass Therapeutics Inc. is for a loss of 12 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Compass Therapeutics Inc. is $9.50, about 70.7% above its last closing price of $2.78

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.11
-0.11
-0.12
Missed
-8.1
Dec. 31 2025
-0.10
-0.10
-0.11
Missed
-12.1
Sep. 30 2024
-0.11
-0.11
-0.08
Beat
29.4​
Jun. 30 2024
-0.09
-0.09
-0.10
Missed
-5.3
​​Mar. 31 2024
-0.11
-0.11
-0.08
Beat
29.1
Dec. 31 2023
-0.09
-0.11
Missed
-16.8​
Sep. 30 2023
-0.11
-0.11
-0.08
Beat
25.3
Jun. 30 2023
-0.08
-0.08
-0.09
Missed
-10.5

This summary was machine generated August 8 at 17:51 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)